Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Manlio Mencoboni, Rosa A. Filiberti, Paola Taveggia, Federica Grosso, Giulia Pasello, Lisette Del Corso, Alberto Muzio, Valentina Polo, Paolo Zucali, Giovanni L. Ceresoli, Hector J. Soto Parra, Laura Auriati, Claudio Simonassi

Research output: Contribution to journalArticlepeer-review


Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalOncology Research and Treatment
Issue number6
Publication statusPublished - Jun 1 2017


  • Chemotherapy
  • Malignant pleural mesothelioma
  • Response
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma'. Together they form a unique fingerprint.

Cite this